Drugs for Ovarian Cancer

Table. Drugs Prescribed for Ovarian Cancer

• Drug name (generic name)
• Drug company
• Indications
• Patient support services

Drug name (generic name)
• Avastin (bevacizumab) Injection
Drug company
• Genentech
Indication
• Treatment of patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer:
  • In combination with carboplatin and paclitaxel, followed by Avastin alone, in patients with stage III or IV disease after surgical resection
  • In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease after 1 or 2 chemotherapy regimens
  • In combination with carboplatin and paclitaxel, or carboplatin and gemcitabine, after Avastin alone, for patients with platinum-sensitive, recurrent disease
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Elahere (mirvetuximab soravtansine-gynx) Injection
Drug company
• ImmunoGen
Indication
• Treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, after 1 to 3 prior systemic treatment regimens
Patient support services
• Co-pay Assistance Program
  833-352-4373
  
  Patient Assistance Program
  833-352-4373

Drug name (generic name)
• Hexalen (altretamine) Capsules
Drug company
• Eisai
Indication
• Ovarian cancer
Patient support services
• This email address is being protected from spambots. You need JavaScript enabled to view it.
  800-769-3880

Drug name (generic name)
• Hycamtin (topotecan) Injection
Drug company
• Novartis
Indication
• Metastatic carcinoma of the ovary
Patient support services
• Novartis Patient Assistance Foundation
  800-277-2254

Drug name (generic name)
• Lynparza (olaparib) Capsules/Tablets
Drug company
• AstraZeneca
Indication
• Maintenance therapy for recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, after complete or partial response to platinum-based chemotherapy
  
  Treatment of advanced ovarian cancer and deleterious or suspected deleterious germline BRCA mutation, after 3 or more lines of chemotherapy
  
  First-line maintenance treatment, in combination with bevacizumab, of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to firstline platinum-based chemotherapy and whose cancer is associated with HRD status, defined by a deleterious or suspected deleterious BRCA mutation and/or genomic instability, as detected by an FDA-approved test
Patient support services
• Lynparza Co-pay Savings Program
  844-275-2360
  
  AZ&Me Prescription Savings Program
  800-292-6363

Drug name (generic name)
• Rubraca (rucaparib) Tablets
Drug company
• Clovis Oncology
Indication
• Treatment of advanced ovarian cancer with deleterious BRCA mutation (germline and/or somatic) after 2 or more chemotherapies
  
  Maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients whose disease is in complete or partial response to platinum-based chemotherapy
Patient support services
• Rubraca $0 Co-Pay Program
  844-779-7707
  
  Clovis Cares Patient Assistance Program
  844-779-7707
  
  Clovis Cares QuickStart Program
  844-779-7707
  
  Clovis Cares Coverage Link Program
  844-779-7707

Drug name (generic name)
• Zejula (niraparib) Capsules
Drug company
• GSK Oncology
Indication
• Treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer after a complete or partial response to platinum-based chemotherapy
  
  Treatment of adults with advanced ovarian, fallopian tube, or primary peritoneal cancer after at least 3 previous chemotherapy regimens, whose cancer is associated with HRD-positive status, defined by a deleterious or suspected deleterious BRCA mutation, or by genomic instability, and whose disease progressed more than 6 months after responding to the last platinum-based chemotherapy
Patient support services
• Together with GSK Oncology Commercial Co-pay Program
  844-447-5662
  
  GSK Patient Assistance Program
  844-447-5662